The combination therapy with IFNα and Tα1 was also evaluated in chronic hepatitis C and proved effective (53), despite earlier reports indicating that Tα1 as single therapy did not show treatment benefits (54, 55). This evidence concerns the gene IFNA1 and chronic hepatitis C virus infection.